Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 242

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 242
---
5.41%
         
        3.44%

        Expected life (in years)

        0.5
         
        0.49
         
        0.49

        Dividend yield

        0%
         
        0%
         
        0%

        Expected volatility

        85.55%
         
        76.27%
         
        77.00%

      Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.Expected Term: The Company uses the simplified method to calculate expected term described in the SEC’s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.

 119

Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.Volatility: Volatility is based on the historical volatility of the Company’s publicly traded shares for the expected term.Restricted Stock UnitsThe following table presents RSU activity under the 2020 Plan as of December 31, 2024: 

        Number ofStock Units

        Weighted-Average Grant Date Fair Value

        Unvested shares December 31, 2023

        236,296

        $
        13.62

        Granted

        952,665

        1.80

        Vested

        (227,379
        )

        13.62

        Forfeited

        (53,916
        )

        3.75

        Unvested shares December 31, 2024

        907,666

        1.80

       As of December 31, 2024, there was $561 of unrecognized compensation cost related to RSUs that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 0.5 years.Stock-based compensation expense recorded under ASC 718 related to stock options and RSUs granted and common stock issued under the 2020 ESPP were allocated to research and development and general and administrative expense as follows: 

        For the Year Ended December 31,

        (in thousands)
         
        2024

        2023

        2022

        Research and development